InsertFile

All vaccines

Abrysvo (RSV)

Abrysvo powder and solvent for solution for injection

Manufacturer
Pfizer Limited
Label last updated
04 Jun 2026
Source
Official SmPC ↗

RSV vaccine, licensed in pregnancy between 28 and 36 weeks to protect newborns, and for adults 18 and over at increased risk. Contains two lab-made RSV surface proteins, no adjuvant.

53 findings, each with the section of the label it comes from.

Ingredients and materials

  • RSV subgroup A stabilised prefusion F antigen 60 micrograms and RSV subgroup B stabilised prefusion F antigen 60 micrograms per 0.5 ml doses.2
  • The F glycoprotein is stabilised in the prefusion conformation - the shape it has before the virus fuses with a cells.2
  • Both antigens are produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technologys.2
  • No adjuvant is listed; the excipients for the powder and a separate water solvent are trometamol, trometamol hydrochloride, sucrose, mannitol (E421), polysorbate 80 (E433), sodium chloride, hydrochloric acid for pH adjustment, and water for injectionss.6.1
  • Contains polysorbate 80, which may cause hypersensitivity reactionss.4.4
  • Declared essentially sodium-free, less than 1 mmol (23 mg) per doses.4.4

Manufacture, storage and handling

  • Shelf life 4 yearss.6.3
  • Store at 2C to 8C, do not freeze, discard if the carton has been frozens.6.4
  • The unopened vial is stable for 5 days at 8C to 30C, but this is to guide professionals in case of a temporary temperature excursion only; use or discard at the end of the periods.6.3
  • Supplied as a powder plus a separate solvent, and must be reconstituted only with the solvent provided, by injecting the whole syringe of solvent into the vial and swirling gently - do not shakes.6.6
  • After reconstitution, administer immediately or within 4 hours if stored between 15C and 30C; if not used immediately, in-use storage is the responsibility of the users.6.3
  • Do not use if large particulate matter or discolouration is founds.6.6
  • Intramuscular injection into the deltoid of the upper arms.4.2
  • Must not be mixed with any other vaccines or medicinal products, and no compatibility studies exists.4.2, 6.2
  • A single 0.5 ml dose; the need for revaccination, and in immunocompromised people the need for a second dose, have not been establisheds.4.2

Safety findings

  • In pregnancy the dose should be given between weeks 28 and 36 of gestations.4.2
  • Has not been studied in pregnancy before 24 weeks and should not be used before 28 weeks. The 28 to 36 week window is described as a precautionary measure until more data are available, to minimise any potential risk of extremely premature births.4.4, 4.6
  • The safety and efficacy of Abrysvo in children from birth to under 18 years have not yet been established; only limited data are available in pregnant adolescents and their infantss.4.2
  • The only listed contraindication is hypersensitivity to the active substances or excipientss.4.3
  • Vaccination should be postponed during acute febrile illness; a minor infection such as a cold is not a reason to defers.4.4
  • Give with caution in thrombocytopenia or any coagulation disorder because bleeding or bruising may occur after intramuscular injections.4.4
  • Safety and immunogenicity have been assessed in immunocompromised individuals including those on immunosuppressant therapy, but 'the efficacy of Abrysvo may be lower in immunosuppressed individuals's.4.4
  • Guillain-Barre syndrome has been reported rarely following vaccination in individuals aged 60 and over, and professionals should be attentive to its signs and symptoms in all recipients to ensure correct diagnosis, initiate supportive care and rule out other causess.4.4, 4.8
  • As with any vaccine, a protective immune response may not be elicited after vaccinations.4.4
  • Anxiety-related reactions including fainting, hyperventilation and stress-related reactions may occur as a response to the needle, so procedures should be in place to avoid injury from faintings.4.4
  • A minimum interval of two weeks is recommended between Abrysvo and a tetanus, diphtheria and acellular pertussis (Tdap) vaccine. There were no safety concerns when the two were given together in healthy non-pregnant women and the RSV A, RSV B, diphtheria and tetanus responses were non-inferior, but the immune responses to the pertussis components were lower and did not meet the criteria for non-inferiority. The clinical relevance of this finding is unknowns.4.5
  • Data on giving Abrysvo at the same time as vaccines other than seasonal flu, COVID-19 mRNA and Tdap vaccines are not availables.4.5
  • In pregnant women the most frequently reported reactions were vaccination site pain (41 per cent), headache (31 per cent) and myalgia (27 per cent), mostly mild to moderate and resolving within 2 to 3 dayss.4.8
  • In individuals 18 and over the most frequent reactions were fatigue (23 per cent), headache (20 per cent), vaccination site pain (19 per cent) and myalgia (16 per cent), mostly mild to moderate and resolving within 1 to 2 dayss.4.8
  • Listed as rare: lymphadenopathy, hypersensitivity reactions including rash and urticaria, and Guillain-Barre syndrome in those aged 60 and overs.4.8
  • Anaphylaxis is listed as very rares.4.8
  • Pregnancy: data on more than 4,000 exposed outcomes indicate no malformative or foeto-neonatal toxicity, and animal studies do not indicate harmful effects on reproductions.4.6
  • In a phase 3 study, maternal adverse events within 1 month of vaccination were similar in the vaccine group (14 per cent) and the placebo group (13 per cent)s.4.6
  • No safety signals were detected in infants up to 24 months of age. Adverse events in infants within 1 month of birth were similar, 38 per cent in the vaccine group against 35 per cent with placebos.4.6
  • Major birth outcomes in the vaccine group against placebo: premature birth 207 (6 per cent) against 172 (5 per cent), low birth weight 186 (5 per cent) against 158 (4 per cent), and congenital anomalies 205 (6 per cent) against 245 (7 per cent)s.4.6
  • The need for revaccination in subsequent pregnancies has not been establisheds.5.1
  • Breastfeeding: it is unknown whether Abrysvo is excreted in human milk, but no adverse effects have been shown in breastfed newborns of vaccinated motherss.4.6
  • Fertility: no human data on the effect on fertility are available; animal studies do not indicate direct or indirect harmful effects on female fertilitys.4.6
  • Overdose: unlikely because of the single dose presentation, with no specific treatment; the individual should be monitored and given symptomatic treatments.4.9

Evidence and claims

  • Efficacy in infants comes from Study 1, a phase 3 randomised double-blind placebo-controlled study: 3,711 pregnant individuals with uncomplicated singleton pregnancies received Abrysvo and 3,709 received placebos.5.1
  • Protection in infants is not from the vaccine acting on the infant but from transplacental transfer of RSV neutralising antibodies from the vaccinated mothers.5.1
  • Against severe medically attended RSV lower respiratory tract disease, efficacy was 81.8 per cent at 90 days, falling to 73.9 per cent at 120 days, 70.9 per cent at 150 days and 69.4 per cent at 180 dayss.5.1
  • Against all medically attended RSV lower respiratory tract disease the effect was roughly half: 57.1 per cent at 90 days, 56.8 per cent at 120, 52.5 per cent at 150 and 51.3 per cent at 180 dayss.5.1
  • The confidence intervals are wide and the case numbers small, for example 19 cases against 62 for severe disease at 180 dayss.5.1
  • In the subgroup vaccinated between weeks 28 and 36 of gestation, efficacy against severe disease was 90.9 per cent at 90 days and 83.8 per cent at 120 days, with even smaller case numbers - 2 against 22, and 5 against 31s.5.1
  • The study population was mostly White (65 per cent), with 20 per cent Black or African American and 29 per cent Hispanic or Latino, a median age of 29, and only 0.2 per cent under 18; the median gestational age at vaccination was 31 weeks and 2 dayss.5.1
  • Safety was evaluated in clinical trials in pregnant women at 24 to 36 weeks (n=3,698) and in individuals aged 18 and over (n=20,275)s.4.8
  • Preclinical data reveal no special hazard for humans based on conventional studies of repeated dose toxicity and toxicity to reproduction and developments.5.3

Document and licensing

  • Marketing authorisation holder: Pfizer Limited, Sandwich, Kents.7
  • Date of first authorisation: 21 November 2023 - one of the newest products heres.9
  • Text last revised May 2026s.10
  • The label states the 28 to 36 week gestational window is a precautionary measure pending more data, and publishes the premature birth and low birth weight rates from the trials.4.6
  • Suspected reactions are reported through the MHRA Yellow Card schemes.4.8

Every line above is a summary of a statement in the manufacturer's own label, with the section number it comes from. Nothing has been added from any other source. The full list of flagged sentences is below, as it came out of the document.

Listed ingredients

Section 2 - qualitative and quantitative composition source ↗

After reconstitution, one dose (0.5 mL) contains:
 RSV subgroup A stabilised prefusion F antigen^1,2 RSV subgroup B stabilised prefusion F antigen^1,2 (RSV antigens) ^1glycoprotein F stabilised in the prefusion conformation ^2produced in Chinese Hamster Ovary cells by recombinant DNA technology.
 60 micrograms ^ 
 60 micrograms ^ 
 For the full list of excipients, see section 6.1.

What these are, in plain English

  • recombinant - Made by genetic engineering: the gene for one piece of the germ is put into a laboratory cell or bacterium, which then makes that piece.

Other ingredients (excipients)

Section 6.1 source ↗

  • Powder
  • TrometamolA buffering agent, used to hold the liquid at a steady acidity so the vaccine does not degrade.
  • Trometamol hydrochlorideA buffering agent, used to hold the liquid at a steady acidity so the vaccine does not degrade.
  • SucroseSugar. Used as a stabiliser so the vaccine keeps its potency in storage.
  • Mannitol (E421)A sugar alcohol used as a stabiliser and bulking agent, so the dried powder forms a proper cake.
  • Polysorbate 80 (E433)An emulsifier (E433), also used in some foods and cosmetics. It stops the ingredients separating.
  • Sodium chlorideSalt. Used to keep the liquid at the same saltiness as the body.
  • Hydrochloric acid (for pH adjustment)A strong acid used in tiny amounts to adjust the acidity of the liquid.
  • Solvent
  • Water for injectionsPurified water to the standard used for injected medicines. It is the liquid the other ingredients are dissolved in.
Audit trail: every flagged sentence in the document (42)

These are the sentences the mechanical filter pulled out, in the document's own words, grouped by section. They are what the briefing above was built from, kept here so you can check nothing was left out. Some are fragments and some are technical, which is why the briefing exists.

4.2 Posology and method of administration

  1. The need for revaccination has not been established.

    Section 4.2 Posology and method of administration source ↗

    In plain English

    • not been established - There is not yet enough evidence to state a conclusion.

    No data / not studied matched: not been established

  2. The need for a second dose has not been established (see section 5.1).

    Section 4.2 Posology and method of administration source ↗

    In plain English

    • not been established - There is not yet enough evidence to state a conclusion.

    No data / not studied matched: not been established

  3. The safety and efficacy of Abrysvo in children (from birth to less than 18 years of age) have not yet been established.

    Section 4.2 Posology and method of administration source ↗

    In plain English

    • efficacy - How well it works in the controlled conditions of a trial.

    Efficacy, effectiveness and endpoints matched: efficacy

  4. Limited data are available in pregnant adolescents and their infants (see section 5.1).

    Section 4.2 Posology and method of administration source ↗

    In plain English

    • limited data - Only a small amount of information exists on this point, so firmer conclusions cannot be drawn.

    Limited, insufficient or inconclusive matched: limited data

4.4 Special warnings and precautions for use

  1. Safety and immunogenicity have been assessed in immunocompromised individuals, including those receiving immunosuppressant therapy (see sections 4.8 and 5.1).

    Section 4.4 Special warnings and precautions for use source ↗

    In plain English

    • immunocompromised - Having a weakened immune system, from illness or from medicines such as chemotherapy.
    • immunogenicity - How strongly the vaccine provokes an immune response. It is measured in the blood, not by how many people avoided the illness.

    Immune system, shedding and transmission matched: immunocompromised

  2. The efficacy of Abrysvo may be lower in immunosuppressed individuals.

    Section 4.4 Special warnings and precautions for use source ↗

    In plain English

    • efficacy - How well it works in the controlled conditions of a trial.

    Efficacy, effectiveness and endpoints matched: efficacy

  3. Abrysvo has not been studied in pregnant individuals less than 24 weeks of gestation and should not be used in pregnant individuals less than 28 weeks of gestation (see sections 4.2, 4.6 and 5.1).

    Section 4.4 Special warnings and precautions for use source ↗

    In plain English

    • has not been studied - No trial has been run for this group or this situation.
    • should not be used - The label says the product should not be given in this situation.

    No data / not studiedNot recommended, contraindicated or restricted matched: has not been studied, should not be used

  4. As with any vaccine, a protective immune response may not be elicited after vaccination.

    Section 4.4 Special warnings and precautions for use source ↗

    Efficacy, effectiveness and endpoints matched: immune response

  5. Guillain-Barré syndrome has been reported rarely following vaccination with Abrysvo in individuals ≥ 60 years (see section 4.8).

    Section 4.4 Special warnings and precautions for use source ↗

    Rare or very rare serious events matched: guillain

  6. Healthcare professionals should be attentive to signs and symptoms of Guillain-Barré syndrome in all Abrysvo recipients to ensure correct diagnosis, in order to initiate adequate supportive care and treatment, and rule out other causes.

    Section 4.4 Special warnings and precautions for use source ↗

    Rare or very rare serious events matched: guillain

  7. Polysorbate 80 may cause hypersensitivity reactions.

    Section 4.4 Special warnings and precautions for use source ↗

    In plain English

    • hypersensitivity - An allergic-type reaction, from a mild rash up to a severe reaction.

    Trace residues and process chemicals matched: polysorbate

4.5 Interaction with other medicinal products and other forms of interaction

  1. • COVID-19 mRNA vaccines, with or without high dose unadjuvanted influenza vaccine administered concomitantly.

    Section 4.5 Interaction with other medicinal products and other forms of interaction source ↗

    In plain English

    • mrna - Messenger RNA: temporary instructions telling cells to make one protein. It does not enter the cell's own DNA.

    Genetic engineering, vectors and GMOs matched: mrna

  2. Immune responses to RSV A, RSV B, diphtheria and tetanus on co-administration were non-inferior to those after separate administration.

    Section 4.5 Interaction with other medicinal products and other forms of interaction source ↗

    Efficacy, effectiveness and endpoints matched: non-inferior

  3. The clinical relevance of this finding is unknown.

    Section 4.5 Interaction with other medicinal products and other forms of interaction source ↗

    No data / not studied matched: is unknown

4.6 Fertility, pregnancy and lactation

  1. It is unknown whether Abrysvo is excreted in human milk.

    Section 4.6 Fertility, pregnancy and lactation source ↗

    No data / not studied matched: is unknown

4.8 Undesirable effects

  1. Not known (cannot be estimated from the available data).

    Section 4.8 Undesirable effects source ↗

    In plain English

    • not known - The label's lowest band: the number of cases is too small, or the reporting too patchy, to work out how often it happens.

    No data / not studied matched: not known

  2. Immunocompromised individuals 18 years of age and older

    Section 4.8 Undesirable effects source ↗

    In plain English

    • immunocompromised - Having a weakened immune system, from illness or from medicines such as chemotherapy.

    Immune system, shedding and transmission matched: immunocompromised

5.1 Pharmacodynamic properties

  1. Abrysvo contains two recombinant stabilised RSV prefusion F antigens representing subgroups RSV-A and RSV-B.

    Section 5.1 Pharmacodynamic properties source ↗

    In plain English

    • recombinant - Made by genetic engineering: the gene for one piece of a germ is put into a lab cell or bacterium, which then makes that piece.

    Genetic engineering, vectors and GMOs matched: recombinant

  2. Following intramuscular administration, the prefusion F antigens elicit an immune response, which protects against RSV-associated lower respiratory tract disease (LRTD).

    Section 5.1 Pharmacodynamic properties source ↗

    Efficacy, effectiveness and endpoints matched: immune response

  3. Study 1 was a phase 3, multicentre, randomised (1:1), double-blind, placebo-controlled study to assess the efficacy of a single dose of Abrysvo in the prevention of RSV-associated LRTD in infants born to pregnant individuals vaccinated between weeks 24 and 36 of gestation.

    Section 5.1 Pharmacodynamic properties source ↗

    In plain English

    • placebo-controlled - A trial where one group gets a dummy instead of the vaccine, so the two can be compared.
    • randomised - A trial where people are assigned to groups by chance.
    • efficacy - How well it works in the controlled conditions of a trial.

    Efficacy, effectiveness and endpoints matched: efficacy

  4. The need for revaccination with subsequent pregnancies has not been established.

    Section 5.1 Pharmacodynamic properties source ↗

    In plain English

    • not been established - There is not yet enough evidence to state a conclusion.

    No data / not studied matched: not been established

  5. Vaccine efficacy (VE) was defined as the relative risk reduction of the endpoint in the Abrysvo group compared to the placebo group for infants born to pregnant individuals who received the assigned intervention.

    Section 5.1 Pharmacodynamic properties source ↗

    In plain English

    • efficacy - How well it works in the controlled conditions of a trial.
    • placebo - A dummy injection with no active ingredient, used as a comparison group in a trial.

    Efficacy, effectiveness and endpoints matched: efficacy

  6. At the primary analysis, there were two primary efficacy endpoints, assessed in parallel, severe RSV-positive medically attended LRTD and RSV-positive medically attended LRTD, occurring within 90, 120, 150 or 180 days after birth.

    Section 5.1 Pharmacodynamic properties source ↗

    In plain English

    • efficacy - How well it works in the controlled conditions of a trial.

    Efficacy, effectiveness and endpoints matched: efficacy

  7. Vaccine efficacy is presented in Tables 2, 3, 4 and 5.

    Section 5.1 Pharmacodynamic properties source ↗

    In plain English

    • efficacy - How well it works in the controlled conditions of a trial.

    Efficacy, effectiveness and endpoints matched: efficacy

  8. Table 2 Vaccine efficacy of Abrysvo against severe medically attended LRTD caused by RSV in infants from birth through 6 months of age by active immunisation of pregnant individuals - Study 1

    Section 5.1 Pharmacodynamic properties source ↗

    In plain English

    • efficacy - How well it works in the controlled conditions of a trial.

    Efficacy, effectiveness and endpoints matched: efficacy

  9. Table 3 Vaccine efficacy of Abrysvo against medically attended LRTD caused by RSV in infants from birth through 6 months of age by active immunisation of pregnant individuals - Study 1

    Section 5.1 Pharmacodynamic properties source ↗

    In plain English

    • efficacy - How well it works in the controlled conditions of a trial.

    Efficacy, effectiveness and endpoints matched: efficacy

  10. Table 4 Vaccine efficacy of Abrysvo against severe medically attended LRTD caused by RSV in infants from birth through 6 months of age by active immunisation of pregnant individuals between weeks 28 and 36 of gestation - Study 1^a

    Section 5.1 Pharmacodynamic properties source ↗

    In plain English

    • efficacy - How well it works in the controlled conditions of a trial.

    Efficacy, effectiveness and endpoints matched: efficacy

  11. Table 5 Vaccine efficacy of Abrysvo against medically attended LRTD caused by RSV in infants from birth through 6 months of age by active immunisation of pregnant individuals between weeks 28 and 36 of gestation - Study 1^a

    Section 5.1 Pharmacodynamic properties source ↗

    In plain English

    • efficacy - How well it works in the controlled conditions of a trial.

    Efficacy, effectiveness and endpoints matched: efficacy

  12. Study 2 was a phase 3, multicentre, randomised, double-blind, placebo-controlled study to assess the efficacy of Abrysvo in the prevention of RSV-associated LRTD in individuals 60 years of age and older.

    Section 5.1 Pharmacodynamic properties source ↗

    In plain English

    • placebo-controlled - A trial where one group gets a dummy instead of the vaccine, so the two can be compared.
    • randomised - A trial where people are assigned to groups by chance.
    • efficacy - How well it works in the controlled conditions of a trial.

    Efficacy, effectiveness and endpoints matched: efficacy

  13. The primary objective was assessment of vaccine efficacy (VE), defined as the relative risk reduction of first episode of RSV-associated LRTD in the Abrysvo group compared to the placebo group in the first RSV season.

    Section 5.1 Pharmacodynamic properties source ↗

    In plain English

    • efficacy - How well it works in the controlled conditions of a trial.
    • placebo - A dummy injection with no active ingredient, used as a comparison group in a trial.

    Efficacy, effectiveness and endpoints matched: efficacy

  14. At the end of the first RSV season the analysis demonstrated statistically significant efficacy for Abrysvo for reduction of RSV-associated LRTD with ≥2 symptoms and with ≥3 symptoms.

    Section 5.1 Pharmacodynamic properties source ↗

    In plain English

    • efficacy - How well it works in the controlled conditions of a trial.

    Efficacy, effectiveness and endpoints matched: efficacy

  15. Vaccine efficacy information at the end of the first RSV season (median follow-up time 7.4 months) is presented in Table 6.

    Section 5.1 Pharmacodynamic properties source ↗

    In plain English

    • efficacy - How well it works in the controlled conditions of a trial.

    Efficacy, effectiveness and endpoints matched: efficacy

  16. Table 6 Vaccine efficacy of Abrysvo against RSV disease - active immunisation of individuals 60 years of age and older - Study 2

    Section 5.1 Pharmacodynamic properties source ↗

    In plain English

    • efficacy - How well it works in the controlled conditions of a trial.

    Efficacy, effectiveness and endpoints matched: efficacy

  17. Vaccine efficacy in the subgroup of participants 80 years of age and older (995 and 981 participants in the Abrysvo and placebo groups, respectively) cannot be concluded due to the low number of total cases accrued (7 cases of RSV-associated LRTD with ≥2 symptoms and 3 cases of RSV-associated LRTD with ≥3 symptoms).

    Section 5.1 Pharmacodynamic properties source ↗

    In plain English

    • efficacy - How well it works in the controlled conditions of a trial.
    • placebo - A dummy injection with no active ingredient, used as a comparison group in a trial.

    Efficacy, effectiveness and endpoints matched: efficacy

  18. Efficacy against RSV-associated lower respiratory tract disease over 2 RSV seasons in individuals 60 years of age and older

    Section 5.1 Pharmacodynamic properties source ↗

    In plain English

    • efficacy - How well it works in the controlled conditions of a trial.

    Efficacy, effectiveness and endpoints matched: efficacy

  19. Vaccine efficacy in individuals 18 through 59 years of age is inferred by immunobridging to study 2 where vaccine efficacy was demonstrated in individuals 60 years of age and older.

    Section 5.1 Pharmacodynamic properties source ↗

    In plain English

    • efficacy - How well it works in the controlled conditions of a trial.

    Efficacy, effectiveness and endpoints matched: efficacy

  20. The non-inferiority criteria were met for high risk individuals 18 through 59 years of age compared to a randomly selected immunogenicity subset (external control group) of individuals ≥60 years of age from study 2 for the ratio of RSV neutralising geometric mean titres (GMTs) by the lower bounds of the 2-sided 95% CIs >0.667 (1.5-fold non-inferiority margin), and for the difference in [...]

    Section 5.1 Pharmacodynamic properties source ↗

    In plain English

    • non-inferiority - A trial designed to show a new vaccine is not worse than an existing one, rather than that it is better.
    • immunogenicity - How strongly the vaccine provokes an immune response. It is measured in the blood, not by how many people avoided the illness.
    • geometric mean - An average used for antibody levels, because those vary over a huge range.

    Efficacy, effectiveness and endpoints matched: geometric mean

  21. Immunogenicity in immunocompromised individuals 18 years of age and older

    Section 5.1 Pharmacodynamic properties source ↗

    In plain English

    • immunocompromised - Having a weakened immune system, from illness or from medicines such as chemotherapy.
    • immunogenicity - How strongly the vaccine provokes an immune response. It is measured in the blood, not by how many people avoided the illness.

    Immune system, shedding and transmission matched: immunocompromised

  22. Study 4 (C3671023 Substudy B) was a Phase 3, single-arm, open-label, multicentre study to assess the safety and immunogenicity of Abrysvo in immunocompromised individuals ≥18 years of age.

    Section 5.1 Pharmacodynamic properties source ↗

    In plain English

    • immunocompromised - Having a weakened immune system, from illness or from medicines such as chemotherapy.
    • immunogenicity - How strongly the vaccine provokes an immune response. It is measured in the blood, not by how many people avoided the illness.

    Immune system, shedding and transmission matched: immunocompromised

  23. Participants had history of a solid organ transplant (kidney, liver, lung or heart) at least 3 months prior to enrollment; end stage renal disease and on haemodialysis; autoimmune inflammatory disorders with active immunomodulator therapy; or advanced non-small cell lung cancer and receiving active immunomodulator therapy.

    Section 5.1 Pharmacodynamic properties source ↗

    Immune system, shedding and transmission matched: autoimmune

6.6 Special precautions for disposal and other handling

  1. Do not use if large particulate matter or discolouration is found.

    Section 6.6 Special precautions for disposal and other handling source ↗

    Not recommended, contraindicated or restricted matched: do not use

  2. Do not use if large particulate matter or discolouration is found.

    Section 6.6 Special precautions for disposal and other handling source ↗

    Not recommended, contraindicated or restricted matched: do not use

Read the whole document at the source ↗